TCTMD

Your source for breaking news, topical videos, and slides covering cardiovascular disease and interventions. Register at

[TCTMD @TCTMD]

Older women with AF fared worse with LAAO than with best medical care, which mostly included DOACs, according to a sex-specific analysis of the CLOSURE-AF trial presented at #ESCCongress2026. No such difference was seen in men. Read more: https://t.co/EjXiTbSk7D

[TCTMD @TCTMD]

On Thursday, September 10th, the US Centers for Medicare & Medicaid Services (CMS) issued its finalized update to the National Coverage Determination (NCD) for TAVI and, as expected, coverage has been extended to patients with asymptomatic severe aortic stenosis. Read more: https://t.co/qUFqaKJV9F

[TCTMD @TCTMD]

We can prevent those first events, and we can reduce your mortality," shares @rgiugliano, lead author of the new VESALIUS-CV trial analysis. Findings indicate that adding evolocumab to lipid-lowering therapy lowers mortality and reduces CV events. https://t.co/RclRqHvkFz

[TCTMD @TCTMD]

SCAI Pokes ABIM Again, This Time Over Procedural Volume Requirements https://t.co/3nGKNSYDX2

[TCTMD @TCTMD]

Beyond Big Hospitals: Where Cardiology Is Headed Next https://t.co/DllETGXLIN

[Cardiovascular Research Foundation @crfheart]

🌎 The world's leading investigators. 🔬 The latest breakthrough science.

Be among the first to explore the research driving tomorrow’s cardiovascular care at the #TCT2026 WorldLink Forum.

This powerhouse program showcases breakthrough studies, first-look data, and emerging innovations from across the globe. Plus, discover more featured clinical research on 11/1 and 11/2.

🔗 Explore the lineup: https://t.co/wyrSTbphPj
🔗 Be there to witness all of it! https://t.co/PZfYsd6AT1

#CardioX #CardioTwitter #CardioEd #CardioResearch @BurkhoffMd @djc795 @ColletCarlos @georgedangas @jgranadacrf @mbmcentegart @Drroxmehran @sahilparikhmd @PopmaJeffrey @triciarawh @mirvatalasnag @TCTConference @TCTMD

[TCTMD @TCTMD]

Global Study Shows Success of ICDs for Preventing Sudden Death in HCM https://t.co/6RFbBwksAg

[TCTMD @TCTMD]

Registry Shines Light on High ASCVD Burden in Arab Americans https://t.co/6HXoJCASbJ

[TCTMD @TCTMD]

The Queen of Hearts artificial intelligence (AI)-powered ECG model has received De Novo authorization from the US Food and Drug Administration for the detection of STEMI and STEMI equivalents in patients with suspected acute coronary syndromes. Read more: https://t.co/W0Z69gePeN

[TCTMD @TCTMD]

Q&A: Haider Warraich on the Quest for Agentic AI Tools for CVD https://t.co/69eigidGH7

[TCTMD @TCTMD]

PREVENT Equations Now in Epic EHRs: Less ‘Friction’ for Clinicians https://t.co/sA7pTeicfC

[TCTMD @TCTMD]

@wfearonmd and @CMichaelGibson break down the final 5-year follow-up of the study comparing FFR-guided PCI vs CABG for patients with three-vessel CAD. Listen to the full discussion:https://t.co/8Wz4pr48nd

[TCTMD @TCTMD]

The FAME 3 Trial https://t.co/ryFXMXuMgs

[TCTMD @TCTMD]

TAVI PCI trial results support individualized decision-making when determining whether to perform TAVI or PCI first for patients with severe aortic stenosis and coronary artery disease. Experts argue that each strategy has its advantages. Read more: https://t.co/Bp1tBwpERL

[TCTMD @TCTMD]

A nurse-led collaborative care model that incorporates mobile health data can increase the number of days alive and out of the hospital in patients who have heart failure with reduced ejection fraction. For more on the TIME-HF findings: https://t.co/MSnKqM7eAI #ESCCongress

[TCTMD @TCTMD]

ESC Recommends CKD Testing in All Patients With CVD https://t.co/4yrp1WgcTQ

[TCTMD @TCTMD]

Updated ESC Heart Failure Guideline Brings Big Changes https://t.co/RXZPBn52iY

[TCTMD @TCTMD]

PRAGUE-26: Catheter-Directed Thrombolysis Beneficial in Intermediate-High-Risk PE https://t.co/Rx4uEUKtPX

[TCTMD @TCTMD]

What challenges will AI pose for medical education going forward? Thomas Lüscher (@ESC_President) shares the mistakes algorithms can make, as well as how they can challenge physicians to better prioritize empathy in patient care. Watch here: https://t.co/1BGaL8uS8v

[TCTMD @TCTMD]

While the Lp(a)HORIZON trial did not find a reduction in CV events by decreasing lp(a) levels with pelacarsen, the results can help to better understand the relationship between lp(a) lowering and CV outcomes. Read the full story: https://t.co/3a8Li2VxkZ